表紙
市場調查報告書

臨床實驗用成像的全球市場:產業趨勢與未來預測

Global Clinical Trial Imaging Market: Industry Trends and Forecast to 2026

出版商 Data Bridge Market Research Private Limited 商品編碼 915524
出版日期 內容資訊 英文 333 Pages
商品交期: 最快1-2個工作天內
價格
臨床實驗用成像的全球市場:產業趨勢與未來預測 Global Clinical Trial Imaging Market: Industry Trends and Forecast to 2026
出版日期: 2019年10月01日內容資訊: 英文 333 Pages
簡介

本報告提供全球臨床實驗用成像市場相關分析,市場基本結構和促進、阻礙因素,整體市場規模趨勢預測,各用途、各種模式、各終端用戶、各流通形態、各地區的詳細趨勢,市場競爭環境,主要企業簡介等調查。

第1章 簡介

第2章 市場區隔

第3章 市場概要

  • 推動市場要素
  • 阻礙市場要素
  • 市場機會
  • 課題

第4章 摘要整理

第5章 重要考察

第6章 全球臨床實驗用成像市場:各產品/服務

  • 概要
  • 服務
    • 手術用成像服務
    • 譯解、分析服務
    • 臨床實驗設計諮詢服務
    • 系統、技術支援服務
  • 軟體

第7章 全球臨床實驗用成像市場:各用途

  • 概要
  • 腫瘤
  • 神經症
  • 內分泌疾病
  • 心臟疾病
  • 皮膚病
  • 血液疾病

第8章 全球臨床實驗用成像市場:各種模式

  • 概要
  • CT (電腦斷層攝影)
  • MRI (核磁共振成像)
  • 超音波
  • PET (陽電子斷層法)
  • X光
  • 心臟超音波
  • 核醫學
  • OCT (光學同調斷層法)
  • 其他

第9章 全球臨床實驗用成像市場:各終端用戶

  • 概要
  • CRO (醫藥品臨床研究委外機構)
  • 醫療設備廠商
  • 製藥企業/生物科技企業
  • 教育機關,政府研究機關

第10章 全球臨床實驗用成像市場:各流通形態

  • 概要
  • 直銷
  • 拍賣

第11章 全球臨床實驗用成像市場:各地區

  • 概要
  • 北美 (美國,加拿大,墨西哥)
  • 歐洲 (德國,法國,英國,義大利,西班牙,瑞士,俄羅斯,荷蘭,比利時,土耳其等)
  • 亞太地區 (中國,日本,韓國,印度,澳洲,新加坡,泰國,馬來西亞,印尼,菲律賓等)
  • 南美 (巴西等)
  • 中東、非洲 (沙烏地阿拉伯,南非等)

第12章 企業環境:臨床實驗用成像市場

  • 各企業佔有率分析:全球整體
  • 各企業佔有率分析:北美市場
  • 各企業佔有率分析:歐洲市場
  • 各企業佔有率分析:亞太地區市場

第13章 企業簡介

  • NAVITAS LIFE SCIENCES
    • 企業概要
    • 市場收益額分析
    • 企業佔有率分析
    • 服務、組合
    • 近幾年的主要趨勢
  • RESONANCE HEALTH
  • BIOTELEMETRY, INC.
  • IXICO PLC
  • ICON PLC
  • IMAGE CORE LAB
  • ANAGRAM 4 CLINICAL TRIALS
  • BIOCLINICA
  • CARDIOVASCULAR IMAGING TECHNOLOGIES
  • ERT CLINICAL
  • INTRINSIC IMAGING
  • LYSCAUT MEDICAL IMAGING COMPANY
  • PAREXEL INTERNATIONAL CORPORATION
  • PERSPECTUM DIAGNOSTICS
  • QUOTIENT SCIENCES
  • RADIANT SAGE LLC
  • WORLDCARE CLINICAL

第14章 調查問卷

第15章 相關分析

目錄

Global clinical trial imaging market is projected to register a substantial CAGR of 6.7% in the forecast period of 2019 to 2026. The new market report contains data for the historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.

Market Segmentation:

By Product & Services (Services, Software), Modality (Computed Tomography, Magnetic Resonance Imaging, Echocardiography, Nuclear Medicine, Positron Emission Tomography, X-Ray, Ultrasound, Optical Coherence Tomography, Others), Application (Oncology, Neurology, Endocrinology, Cardiology, Dermatology, Hematology, Others), End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic and Government Research Institutes, Medical Device Manufacturers , Others), Distribution Channel (Direct Sales, Tender Sales), Geography (Europe, North America, Asia-Pacific, South America, Middle East and Africa)

Some of the major factors contributing to the growth of the global clinical trial imaging market:

  • Increasing health care expenditure
  • Increasing number of pipeline products for treatment of various diseases

Market Players:

The key market players for global clinical trial imaging market are listed below:

  • BioTelemetry, Inc
  • IXICO plc
  • Resonance Health
  • Bioclinica, ICON plc
  • Radiant Sage LLC
  • Lyscaut Medical Imaging Company
  • Quotient Sciences
  • worldcare Clinical
  • Navitas Life Sciences
  • Cardiovascular Imaging Technologies
  • Intrinsic Imaging
  • Image Core Lab
  • ERT Clinical
  • Perspectum Diagnostics
  • Anagram 4 clinical trials
  • Parexel International Corporation

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF GLOBAL CLINICAL TRIAL IMAGING MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GLOBAL CLINICAL TRIAL IMAGING MARKET: GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.7 GLOBAL CLINICAL TRIAL IMAGING MARKET: DBMR MARKET POSITION GRID
  • 2.8 DBMR VENDOR SHARE ANALYSIS
  • 2.9 MULTIVARIATE MODELING
  • 2.10 PRODUCTS LIFELINE CURVE
  • 2.11 SECONDARY SOURCES
  • 2.12 ASSUMPTIONS

3 MARKET OVERVIEW

  • 3.1 DRIVERS
    • 3.1.1 RISING R&D EXPENDITURE
    • 3.1.2 INCREASING NUMBER OF CONTRACT RESEARCH ORGANIZATION
    • 3.1.3 INCREASING PREVALENCE OF CHRONIC DISEASES
    • 3.1.4 GROWTH IN THE PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES
  • 3.2 RESTRAINTS
    • 3.2.1 HIGH RISK RADIATION CAUSING DISEASES
    • 3.2.2 HIGH IMPLEMENTATION COST OF IMAGING SYSTEMS
  • 3.3 OPPORTUNITIES
    • 3.3.1 STRATEGIC INITIATIVES FOR BUSINESS EXPANSION
    • 3.3.2 DEVELOPMENT OF INNOVATIVE IMAGING MODALITIES AND CONTRAST AGENTS
    • 3.3.3 EMERGING ECONOMIES
  • 3.4 CHALLENGES
    • 3.4.1 STRICT REGULATORY POLICIES
    • 3.4.2 COST OF CLINICAL TRIALS

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

6 GLOBAL CLINICAL TRIAL IMAGINGMARKET, BY PRODUCT AND SERVICES

  • 6.1 OVERVIEW
  • 6.2 SERVICES
    • 6.2.1 OPERATIONAL IMAGING SERVICES
    • 6.2.2 READ ANALYSIS SERVICES
    • 6.2.3 TRIAL DESIGN CONSULTING SERVICES
    • 6.2.4 SYSTEM AND TECHNICAL SUPPORT SERVICES
  • 6.3 SOFTWARE

7 GLOBAL CLINICAL TRIAL IMAGING MARKET, BY APPLICATION

  • 7.1 OVERVIEW
  • 7.2 ONCOLOGY
    • 7.2.1 ECHOCARDIOGRAPHY
    • 7.2.2 MAGNETIC RESONANCE IMAGING
    • 7.2.3 COMPUTED TOMOGRAPHY
    • 7.2.4 POSITRON EMISSION TOMOGRAPHY
    • 7.2.5 NUCLEAR MEDICINE
    • 7.2.6 X-RAY
    • 7.2.7 ULTRASOUND
    • 7.2.8 OPTICAL COHERENCE TOMOGRAPHY
    • 7.2.9 OTHERS
  • 7.3 NEUROLOGY
    • 7.3.1 COMPUTED TOMOGRAPHY
    • 7.3.2 MAGNETIC RESONANCE IMAGING
    • 7.3.3 POSITRON EMISSION TOMOGRAPHY
    • 7.3.4 NUCLEAR MEDICINE
    • 7.3.5 X-RAY
    • 7.3.6 ULTRASOUND
    • 7.3.7 OPTICAL COHERENCE TOMOGRAPHY
    • 7.3.8 OTHERS
  • 7.4 ENDOCRINOLOGY
    • 7.4.1 COMPUTED TOMOGRAPHY
    • 7.4.2 MAGNETIC RESONANCE IMAGING
    • 7.4.3 POSITRON EMISSION TOMOGRAPHY
    • 7.4.4 NUCLEAR MEDICINE
    • 7.4.5 X-RAY
    • 7.4.6 ULTRASOUND
    • 7.4.7 OPTICAL COHERENCE TOMOGRAPHY
    • 7.4.8 OTHERS
  • 7.5 CARDIOLOGY
    • 7.5.1 X-RAY
    • 7.5.2 ULTRASOUND
    • 7.5.3 COMPUTED TOMOGRAPHY
    • 7.5.4 MAGNETIC RESONANCE IMAGING
    • 7.5.5 NUCLEAR MEDICINE
    • 7.5.6 POSITRON EMISSION TOMOGRAPHY
    • 7.5.7 OPTICAL COHERENCE TOMOGRAPHY
    • 7.5.8 ECHOCARDIOGRAPHY
    • 7.5.9 OTHERS
  • 7.6 DERMATOLOGY
    • 7.6.1 ULTRASOUND
    • 7.6.2 X-RAY
    • 7.6.3 MAGNETIC RESONANCE IMAGING
    • 7.6.4 COMPUTED TOMOGRAPHY
    • 7.6.5 OPTICAL COHERENCE TOMOGRAPHY
    • 7.6.6 POSITRON EMISSION TOMOGRAPHY
    • 7.6.7 NUCLEAR MEDICINE
    • 7.6.8 OTHERS
  • 7.7 HEMATOLOGY
    • 7.7.1 ULTRASOUND
    • 7.7.2 COMPUTED TOMOGRAPHY
    • 7.7.3 MAGNETIC RESONANCE IMAGING
    • 7.7.4 X-RAY
    • 7.7.5 POSITRON EMISSION TOMOGRAPHY
    • 7.7.6 NUCLEAR MEDICINE
    • 7.7.7 OPTICAL COHERENCE TOMOGRAPHY
    • 7.7.8 ECHOCARDIOGRAPHY
    • 7.7.9 OTHERS

8 GLOBAL CLINICAL TRIAL IMAGINGMARKET, BY MODALITY

  • 8.1 OVERVIEW
  • 8.2 COMPUTED TOMOGRAPHY
  • 8.3 MAGNETIC RESONANCE IMAGING
  • 8.4 ULTRASOUND
  • 8.5 POSITRON EMISSION TOMOGRAPHY
  • 8.6 X-RAY
  • 8.7 ECHOCARDIOGRAPHY
  • 8.8 NUCLEAR MEDICINE
  • 8.9 OPTICAL COHERENCE TOMOGRAPHY
  • 8.10 OTHERS

9 GLOBAL CLINICAL TRIAL IMAGINGMARKET, BY END USER

  • 9.1 OVERVIEW
  • 9.2 CONTRACT RESEARCH ORGANIZATION
  • 9.3 MEDICAL DEVICE MANUFACTURERS
  • 9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 9.5 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES

10 GLOBAL CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR

  • 10.1 OVERVIEW
  • 10.2 DIRECT SALES
  • 10.3 TENDERS SALES

11 GLOBAL CLINICAL TRIAL IMAGING MARKET, BY GEOGRAPHY

  • 11.1 OVERVIEW
  • 11.2 NORTH AMERICA
    • 11.2.1 U.S.
    • 11.2.2 CANADA
    • 11.2.3 MEXICO
  • 11.3 EUROPE
    • 11.3.1 GERMANY
    • 11.3.2 FRANCE
    • 11.3.3 U.K.
    • 11.3.4 ITALY
    • 11.3.5 SPAIN
    • 11.3.6 SWITZERLAND
    • 11.3.7 RUSSIA
    • 11.3.8 NETHERLANDS
    • 11.3.9 BELGIUM
    • 11.3.10 TURKEY
    • 11.3.11 REST OF EUROPE
  • 11.4 ASIA-PACIFIC
    • 11.4.1 CHINA
    • 11.4.2 JAPAN
    • 11.4.3 SOUTH KOREA
    • 11.4.4 INDIA
    • 11.4.5 AUSTRALIA
    • 11.4.6 SINGAPORE
    • 11.4.7 THAILAND
    • 11.4.8 MALAYSIA
    • 11.4.9 INDONESIA
    • 11.4.10 PHILIPPINES
    • 11.4.11 REST OF ASIA-PACIFIC
  • 11.5 SOUTH AMERICA
    • 11.5.1 BRAZIL
    • 11.5.2 REST OF SOUTH AMERICA
  • 11.6 MIDDLE EAST AND AFRICA
    • 11.6.1 SAUDI ARABIA
    • 11.6.2 SOUTH AFRICA
    • 11.6.3 REST OF MEA

12 GLOBAL CLINICAL TRIAL IMAGING MARKET, COMPANY LANDSCAPE

  • 12.1 COMPANY SHARE ANALYSIS: GLOBAL
  • 12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
  • 12.3 COMPANY SHARE ANALYSIS: EUROPE
  • 12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

13 COMPANY PROFILE

  • 13.1 NAVITAS LIFE SCIENCES
    • 13.1.1 COMPANY SNAPSHOT
    • 13.1.2 REVENUE ANALYSIS
    • 13.1.3 COMPANY SHARE ANALYSIS
    • 13.1.4 SERVICE PORTFOLIO
    • 13.1.5 RECENT DEVELOPMENTS
  • 13.2 RESONANCE HEALTH
    • 13.2.1 COMPANY SNAPSHOT
    • 13.2.2 REVENUE ANALYSIS
    • 13.2.3 COMPANY SHARE ANALYSIS
    • 13.2.4 SERVICE PORTFOLIO
    • 13.2.5 RECENT DEVELOPMENTS
  • 13.3 BIOTELEMETRY, INC.
    • 13.3.1 COMPANY SNAPSHOT
    • 13.3.2 REVENUE ANALYSIS
    • 13.3.3 COMPANY SHARE ANALYSIS
    • 13.3.4 SERVICEPORTFOLIO
    • 13.3.5 RECENT DEVELOPMENTS
  • 13.4 IXICO PLC
    • 13.4.1 COMPANY SNAPSHOT
    • 13.4.2 REVENUE ANALYSIS
    • 13.4.3 COMPANY SHARE ANALYSIS
    • 13.4.4 SERVICE PORTFOLIO
    • 13.4.5 RECENT DEVELOPMENTS
  • 13.5 ICON PLC
    • 13.5.1 COMPANY SNAPSHOT
    • 13.5.2 REVENUE ANALYSIS
    • 13.5.3 COMPANY SHARE ANALYSIS
    • 13.5.4 SERVICE PORTFOLIO
    • 13.5.5 RECENT DEVELOPMENTS
  • 13.6 IMAGE CORE LAB
    • 13.6.1 COMPANY SNAPSHOT
    • 13.6.2 SERVICE PORTFOLIO
    • 13.6.3 RECENT DEVELOPMENT
  • 13.7 ANAGRAM 4 CLINICAL TRIALS
    • 13.7.1 COMPANY SNAPSHOT
    • 13.7.2 SERVICE PORTFOLIO
    • 13.7.3 RECENT DEVELOPMENT
  • 13.8 BIOCLINICA
    • 13.8.1 COMPANY SNAPSHOT
    • 13.8.2 SERVICE PORTFOLIO
    • 13.8.3 RECENT DEVELOPMENTS
  • 13.9 CARDIOVASCULAR IMAGING TECHNOLOGIES
    • 13.9.1 COMPANY SNAPSHOT
    • 13.9.2 PRODUCT PORTFOLIO
    • 13.9.3 RECENT DEVELOPMENT
  • 13.10 ERT CLINICAL
    • 13.10.1 COMPANY SNAPSHOT
    • 13.10.2 SERVICE PORTFOLIO
    • 13.10.3 RECENT DEVELOPMENTS
  • 13.11 INTRINSIC IMAGING
    • 13.11.1 COMPANY SNAPSHOT
    • 13.11.2 PRODUCT PORTFOLIO
    • 13.11.3 SERVICE PORTFOLIO
    • 13.11.4 RECENT DEVELOPMENTS

  • 13.12 LYSCAUT MEDICAL IMAGING COMPANY
    • 13.12.1 COMPANY SNAPSHOT
    • 13.12.2 SERVICE PORTFOLIO
    • 13.12.3 RECENT DEVELOPMENT
  • 13.13 PAREXEL INTERNATIONAL CORPORATION
    • 13.13.1 COMPANY SNAPSHOT
    • 13.13.2 SERVICE PORTFOLIO
    • 13.13.3 RECENT DEVELOPMENTS
  • 13.14 PERSPECTUM DIAGNOSTICS
    • 13.14.1 COMPANY SNAPSHOT
    • 13.14.2 PRODUCT PORTFOLIO
    • 13.14.3 SERVICE PORTFOLIO
    • 13.14.4 RECENT DEVELOPMENTS
  • 13.15 QUOTIENT SCIENCES
    • 13.15.1 COMPANY SNAPSHOT
    • 13.15.2 SERVICE PORTFOLIO
    • 13.15.3 RECENT DEVELOPMENTS
  • 13.16 RADIANT SAGE LLC
    • 13.16.1 COMPANY SNAPSHOT
    • 13.16.2 PRODUCT PORTFOLIO
    • 13.16.3 SERVICE PORTFOLIO
    • 13.16.4 RECENT DEVELOPMENTS
  • 13.17 WORLDCARE CLINICAL
    • 13.17.1 COMPANY SNAPSHOT
    • 13.17.2 SERVICE PORTFOLIO
    • 13.17.3 RECENT DEVELOPMENTS

14 QUESTIONNAIRE

15 RELATED REPORTS

LIST OF FIGURES

  • FIGURE 1 GLOBAL CLINICAL TRIAL IMAGING MARKET: SEGMENTATION
  • FIGURE 2 GLOBAL CLINICAL TRIAL IMAGING MARKET: DATA TRIANGULATION
  • FIGURE 3 GLOBAL CLINICAL TRIAL IMAGING MARKET: DROC ANALYSIS
  • FIGURE 4 GLOBAL CLINICAL TRIAL IMAGING MARKET: GLOBAL VS REGIONAL ANALYSIS
  • FIGURE 5 GLOBAL CLINICAL TRIAL IMAGING MARKET: COMPANY RESEARCH ANALYSIS
  • FIGURE 6 GLOBAL CLINICAL TRIAL IMAGING MARKET: INTERVIEW DEMOGRAPHICS
  • FIGURE 7 GLOBAL CLINICAL TRIAL MARKET: DBMR VENDOR SHARE ANALYSIS
  • FIGURE 8 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE GLOBAL CLINICAL TRIAL IMAGING MARKET
  • FIGURE 9 WORLDWIDE BIOPHARMA COMPANIES R&D EXPENDITURE (IN MILLION U.S. DOLLARS)
  • FIGURE 10 THE MARKET GROWTH IN CLINICAL CRO (IN USD MILLIONS)
  • FIGURE 11 THE FUNCTION OF CRO
  • FIGURE 12 PHARMACEUTICAL RESEARCHES AND DEVELOPMENT EXPENDITURE FROM 2010 TO 2018 (IN MILLION U.S. DOLLARS)
  • FIGURE 13 RADIOLOGY SOCIETY OF NORTH AMERICA (RSNA) PUBLISHED EXPOSURE OF RADIATION FACED BY THE U.S. CITIZEN IN 2012
  • FIGURE 14 GLOBAL CLINICAL TRIAL IMAGING MARKET: SEGMENTATION
  • FIGURE 15 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE GLOBAL CLINICAL TRIAL MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE INCREASING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2019 TO 2026
  • FIGURE 16 INCREASING NUMBER OF CONTRACT RESEARCH ORGANIZATIONS AND RISING R&D EXPENDITURE ARE EXPECTED TO DRIVE THE GLOBAL CLINICAL TRIAL IMAGING MARKET IN THE FORECAST PERIOD OF 2019 TO 2026
  • FIGURE 17 SERVICES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL CLINICAL TRIAL IMAGING MARKET IN 2019
  • FIGURE 18 NORTH AMERICA IS THE HIGHEST MARKET SHARE AND ASIA-PAIFIC IS THE MAXIMUM GROWING FOR GLOBAL CLINICAL TRIAL IMAGING MARKET IN THE FORECAST PERIOD OF 2019 TO 2026
  • FIGURE 19 GLOBAL CLINICAL TRIAL IMAGING MARKET DOMINATED BY SERVICES (2019)
  • FIGURE 20 GLOBAL CLINICAL TRIAL IMAGING MARKET, BY PRODUCT AND SERVICES, 2017-2026 (USD MILLION)
  • FIGURE 21 GLOBAL CLINICAL TRIAL IMAGING MARKET: BY PRODUCT AND SERVICES, CAGR (2017-2026)
  • FIGURE 22 GLOBAL CLINICAL TRIAL IMAGING MARKET: BY PRODUCT AND SERVICES, LIFELINE CURVE
  • FIGURE 23 GLOBAL CLINICAL TRIAL IMAGING MARKET DOMINATED BY APPLICATION (2019)
  • FIGURE 24 GLOBAL CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • FIGURE 25 GLOBAL CLINICAL TRIAL IMAGING MARKET: BY APPLICATION, CAGR (2017-2026)
  • FIGURE 26 GLOBAL CLINICAL TRIAL IMAGING MARKET: BY APPLICATION, LIFELINE CURVE
  • FIGURE 27 GLOBAL CLINICAL TRIAL IMAGING MARKET DOMINATED BY MODALITY (2019)
  • FIGURE 28 GLOBAL CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2017-2026 (USD MILLION)
  • FIGURE 29 GLOBAL CLINICAL TRIAL IMAGING MARKET: BY MODALITY, CAGR (2017-2026)
  • FIGURE 30 GLOBAL CLINICAL TRIAL IMAGING MARKET: BY MODALITY, LIFELINE CURVE
  • FIGURE 31 GLOBAL CLINICAL TRIAL IMAGING MARKET DOMINATED BY END USER (2019)
  • FIGURE 32 GLOBAL CLINICAL TRIAL IMAGING MARKET, BY END USER, 2017-2026 (USD MILLION)
  • FIGURE 33 GLOBAL CLINICAL TRIAL IMAGING MARKET: BY END USER, CAGR (2017-2026)
  • FIGURE 34 GLOBAL CLINICAL TRIAL IMAGING MARKET: BY END USER, LIFELINE CURVE
  • FIGURE 35 GLOBAL CLINICAL TRIAL IMAGING MARKET DOMINATED BY DISTRIBUTOR (2019)
  • FIGURE 36 GLOBAL CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2017-2026 (USD MILLION)
  • FIGURE 37 GLOBAL CLINICAL TRIAL IMAGING MARKET: BY DISTRIBUTOR, CAGR (2017-2026)
  • FIGURE 38 GLOBAL CLINICAL TRIAL IMAGING MARKET: BY DISTRIBUTOR, LIFELINE CURVE
  • FIGURE 39 GLOBAL CLINICAL TRIAL IMAGING MARKET: SNAPSHOT (2018)
  • FIGURE 40 GLOBAL CLINICAL TRIAL IMAGING MARKET: BY GEOGRAPHY (2018)
  • FIGURE 41 GLOBAL CLINICAL TRIAL IMAGING MARKET: BY GEOGRAPHY (2019 & 2026)
  • FIGURE 42 GLOBAL CLINICAL TRIAL IMAGING MARKET: BY GEOGRAPHY (2018 & 2026)
  • FIGURE 43 GLOBAL CLINICAL TRIAL IMAGING MARKET: BY PRODUCT AND SERVICES (2019-2026)
  • FIGURE 44 NORTH AMERICA CLINICAL TRIAL IMAGING MARKET: SNAPSHOT (2018)
  • FIGURE 45 NORTH AMERICA CLINICAL TRIAL IMAGING MARKET: BY COUNTRY (2018)
  • FIGURE 46 NORTH AMERICA CLINICAL TRIAL IMAGING MARKET: BY COUNTRY (2019)
  • FIGURE 47 NORTH AMERICA CLINICAL TRIAL IMAGING MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 48 NORTH AMERICA CLINICAL TRIAL IMAGING MARKET: BY PRODUCT AND SERVICES (2019 - 2026)
  • FIGURE 49 EUROPE CLINICAL TRIAL IMAGING MARKET: SNAPSHOT (2018)
  • FIGURE 50 EUROPE CLINICAL TRIAL IMAGING MARKET: BY COUNTRY (2018)
  • FIGURE 51 EUROPE CLINICAL TRIAL IMAGING MARKET: BY COUNTRY (2019)
  • FIGURE 52 EUROPE CLINICAL TRIAL IMAGING MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 53 EUROPE CLINICAL TRIAL IMAGING MARKET: BY PRODUCT AND SERVICES (2019 - 2026)
  • FIGURE 54 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SNAPSHOT (2018)
  • FIGURE 55 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET: BY COUNTRY (2018)
  • FIGURE 56 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET: BY COUNTRY (2019)
  • FIGURE 57 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 58 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET: BY PRODUCT & SERVICES (2019 - 2026)
  • FIGURE 59 SOUTH AMERICA CLINICAL TRIAL IMAGING MARKET: SNAPSHOT (2018)
  • FIGURE 60 SOUTH AMERICA CLINICAL TRIAL IMAGING MARKET: BY COUNTRY (2018)
  • FIGURE 61 SOUTH AMERICA CLINICAL TRIAL IMAGING MARKET: BY COUNTRY (2019)
  • FIGURE 62 SOUTH AMERICA CLINICAL TRIAL IMAGING MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 63 FIGURE 5 SOUTH AMERICA CLINICAL TRIAL IMAGING MARKET: BY PRODUCT & SERVICES (2019 - 2026)
  • FIGURE 64 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET: SNAPSHOT (2018)
  • FIGURE 65 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET: BY COUNTRY (2018)
  • FIGURE 66 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET: BY COUNTRY (2019)
  • FIGURE 67 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 68 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET: BY PRODUCT & SERVICES (2019 - 2026)
  • FIGURE 69 GLOBAL CLINICAL TRIAL IMAGING MARKET: COMPANY SHARE 2018 (%)
  • FIGURE 70 NORTH AMERICA CLINICAL TRIAL IMAGING MARKET: COMPANY SHARE 2018 (%)
  • FIGURE 71 EUROPE CLINICAL TRIAL IMAGING MARKET: COMPANY SHARE 2018 (%)
  • FIGURE 72 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET: COMPANY SHARE 2018 (%)